Association Between Serum Levels of the Soluble Receptor (sRAGE) for Advanced Glycation Endproducts (AGEs) and their Receptor (RAGE) in Peripheral Blood Mononuclear Cells of Children with Type 1 Diabetes Mellitus

被引:20
作者
Dettoraki, Athina [1 ]
Gil, Andrea Paola Rojas [1 ]
Spiliotis, Bessie E. [1 ]
机构
[1] Univ Patras, Sch Med, Dept Pediat, Div Pediat Endocrinol & Diabet, Patras 16504, Greece
关键词
type 1 diabetes mellitus; advanced glycation endproducts; RAGE; sRAGE; END-PRODUCTS; N-EPSILON-(CARBOXYMETHYL)LYSINE; COMPLICATIONS; INTERVENTION; ADOLESCENTS; ROLES;
D O I
10.1515/JPEM.2009.22.10.895
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: The binding of AGEs to RAGE is involved in diabetic vascular complications. We studied sRAGE levels and RAGE protein expression (P) together with N-carboxymethyl lysine (CML), a major AGE, in 74 patients with type I diabetes mellitus (DM1) and 43 healthy (C) children. Methods: sRAGE and CML levels were determined by ELISA and RAGE P was evaluated in mononuclear cells by Western immunoblotting. Results: Serum sRAGE was higher in DM1 than in C (1430 +/- 759 vs 1158 +/- 595 pg/ml, p = 0.047), inversely correlated to diabetes duration (r = -0.265, p = 0.037) and directly correlated to LDL-cholesterol levels (r = 0.224, p = 0.039). Diabetes duration correlated independently with sRAGE (p = 0.034). Circulating CML levels were not significantly different between DM1 and C groups (3.51 +/- 1.49 vs 3.59 +/- 1.83 ng/ml, p > 0.05) and RAGE P was lower in DM1 than in C (61 +/- 46 vs 102 +/- 63%, p = 0.0001). Conclusions: Increased serum sRAGE in children with DM1 may provide temporary protection against cell damage and may be sufficient to eliminate excessive circulating CML.
引用
收藏
页码:895 / 904
页数:10
相关论文
共 22 条
  • [1] Advanced glycation endproducts - role in pathology of diabetic complications
    Ahmed, N
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 67 (01) : 3 - 21
  • [2] Biochemistry and molecular cell biology of diabetic complications
    Brownlee, M
    [J]. NATURE, 2001, 414 (6865) : 813 - 820
  • [3] RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice
    Bucciarelli, LG
    Wendt, T
    Qu, W
    Lu, Y
    Lalla, E
    Rong, LL
    Goova, MT
    Moser, B
    Kislinger, T
    Lee, DC
    Kashyap, Y
    Stern, DM
    Schmidt, AM
    [J]. CIRCULATION, 2002, 106 (22) : 2827 - 2835
  • [4] Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes
    Challier, M
    Jacqueminet, S
    Benabdesselam, O
    Grimaldi, A
    Beaudeux, JL
    [J]. CLINICAL CHEMISTRY, 2005, 51 (09) : 1749 - 1750
  • [5] Calcium-regulated intramembrane proteolysis of the RAGE receptor
    Galichet, Arnaud
    Weibel, Mirjarn
    Heimann, Claus W.
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2008, 370 (01) : 1 - 5
  • [6] Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and Nε-(carboxymethyl) lysine ELISA
    Galler, A
    Müller, G
    Schinzel, R
    Kratzsch, J
    Kiess, W
    Münch, G
    [J]. DIABETES CARE, 2003, 26 (09) : 2609 - 2615
  • [7] Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE)
    Hanford, LE
    Enghild, JJ
    Valnickova, Z
    Petersen, SV
    Schaefer, LM
    Schaefer, TM
    Reinhart, TA
    Oury, TD
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (48) : 50019 - 50024
  • [8] Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease - The next C-reactive protein?
    Hudson, BI
    Harja, E
    Moser, B
    Schmidt, AM
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (05) : 879 - 882
  • [9] Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders
    Hudson, BI
    Bucciarelli, LG
    Wendt, T
    Sakaguchi, T
    Lalla, E
    Qu, W
    Lu, Y
    Lee, L
    Stern, DM
    Naka, Y
    Ramasamy, R
    Yan, SD
    Yan, SF
    D'Agati, V
    Schmidt, AM
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 419 (01) : 80 - 88
  • [10] Diabetes and advanced glycoxidation end products
    Huebschmann, Amy G.
    Regensteiner, Judith G.
    Vlassara, Helen
    Reusch, Jane E. B.
    [J]. DIABETES CARE, 2006, 29 (06) : 1420 - 1432